TrialClinics (Sao Paulo, Brazil)2012

Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study.

José Gomes Batista et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.